Calidi Biotherapeutics (CLDI) Preferred Stock Liabilities (2021 - 2023)
Calidi Biotherapeutics (CLDI) posted quarterly Preferred Stock Liabilities of $43.2 million for Q2 2023, down 81.23% year-over-year from $230.2 million in Q2 2022, and up 0.72% quarter-over-quarter from $42.9 million in Q1 2023.
Calidi Biotherapeutics (CLDI) Preferred Stock Liabilities (2021 - 2023) Analysis & Trends
Calidi Biotherapeutics' Preferred Stock Liabilities history runs 3 years deep, the most recent figure standing at $43.2 million for Q2 2023.
- In Q2 2023, Preferred Stock Liabilities fell 81.23% year-over-year to $43.2 million; the TTM figure through Jun 2023 stood at $43.2 million (down 81.23% YoY), while the FY2022 annual figure was $1.4 million, down 99.41% from the prior year.
- Preferred Stock Liabilities for Q2 2023 stood at $43.2 million, up from $42.9 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $230.2 million in Q2 2022, with the low at $1.4 million in Q4 2022.
- The 3-year median for Preferred Stock Liabilities is $43.2 million (2023), against an average of $117.1 million.
- The sharpest annual moves came in 2022 and 2023: Preferred Stock Liabilities slumped 99.41% in 2022, then plunged 81.23% in 2023.
- Calidi Biotherapeutics' Preferred Stock Liabilities stood at $230.0 million in 2021, then plunged by 99.41% to $1.4 million in 2022, then soared by 3091.6% to $43.2 million in 2023.
- Business Quant data shows CLDI's Preferred Stock Liabilities at $43.2 million in Q2 2023, $42.9 million in Q1 2023, and $1.4 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 43.21 Mn |
| Mar 31, 2023 | 42.91 Mn |
| Dec 31, 2022 | 1.35 Mn |
| Sep 30, 2022 | 41.68 Mn |
| Jun 30, 2022 | 230.18 Mn |
| Mar 31, 2022 | 230.02 Mn |
| Dec 31, 2021 | 230.00 Mn |